Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 47Carcinoma, Hepatocellular 9Triple Negative Breast Neoplasms 7Stomach Neoplasms 6Inflammatory Breast Neoplasms 6Lymphoma, Large B-Cell, Diffuse 4Urinary Bladder Neoplasms 3Non-Muscle Invasive Bladder Neoplasms 3Esophageal Neoplasms 3Recurrence 2Lymphoma 2Breast Neoplasms, Male 2Breast Diseases 2Upper Tract Urothelial Carcinoma 1Thymoma 1Small Cell Lung Cancer Extensive Stage 1Sarcoma 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Postoperative Complications 1Pancreatic Neoplasms 1Oesophagogastric Cancer 1Neoplastic Cells, Circulating 1Neoplasms, Unknown Primary 1Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lung Neoplasms 1Liver Neoplasms 1Leiomyosarcoma 1

Interventions

N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 14Cyclophosphamide 9Prednisone 8Etoposide 6Vincristine 5Gemcitabine 5Lenalidomide 4Doxorubicin 4Dexamethasone 3Azacitidine 3liposomal doxorubicin 2endostar protein 2apatinib 2VAP-cyclo protocol 2Ifosfamide 2Cisplatin 2sintilimab 1romidepsin 1ivarmacitinib 1fludarabine phosphate 1fludarabine 1camrelizumab 1Vinorelbine 1Valproic Acid 1Transplantation, Autologous 1TQ-B3525 1Rituximab 1Prednisolone 1Polymerase Chain Reaction 1Oxaliplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Lymphoma, T-Cell, Peripheral × Epirubicin × Clear all
NCT04061772 2019-08-20

A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma

Zhejiang Cancer Hospital

Phase 2 Unknown
54 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡